How long you take omeprazole after gastric sleeve surgery is one of the most common questions following bariatric procedures in the UK. Omeprazole — a proton pump inhibitor (PPI) — is routinely prescribed after sleeve gastrectomy to protect the healing gastric lining, reduce acid reflux, and support recovery. However, the appropriate duration varies between patients and surgical centres. This article explains why omeprazole is prescribed, how long most NHS bariatric units recommend taking it, what UK guidance says about long-term PPI use, and when to seek a medication review from your GP or bariatric team.

Why Omeprazole Is Prescribed After Gastric Sleeve Surgery

Omeprazole is prescribed after sleeve gastrectomy to reduce gastric acid, protect the healing gastric lining and staple line, and relieve reflux symptoms caused by altered stomach anatomy and motility.

Omeprazole is a proton pump inhibitor (PPI) that works by blocking the hydrogen-potassium ATPase enzyme system in the stomach's parietal cells, thereby reducing the production of gastric acid. After a sleeve gastrectomy — one of the most commonly performed bariatric procedures in the UK — the stomach is surgically reduced to a narrow, tube-shaped pouch (approximately 15–20% of its original volume, though this varies). This structural change significantly alters the stomach's anatomy and its relationship with the oesophagus.

Following surgery, the reduced stomach volume and changes in gastric motility can increase the risk of acid reflux and irritation to the gastric lining. Omeprazole is prescribed primarily to:

• Reduce acid-related irritation and ulceration of the gastric lining and surgical staple line during the early postoperative period

• Relieve symptoms of acid reflux and heartburn, which are common in the weeks following surgery

• Support healing by maintaining a less acidic environment during recovery

It is important to note that PPIs do not prevent staple-line leakage, which is a multifactorial surgical complication unrelated to acid suppression.

Omeprazole is generally well tolerated, but long-term use is associated with potential risks including hypomagnesaemia (low magnesium), vitamin B12 deficiency, increased risk of Clostridioides difficile infection, and a modest increase in fracture risk — as highlighted in MHRA Drug Safety Updates. These considerations are particularly relevant in bariatric patients, who are already at risk of nutritional deficiencies. Your surgical team will weigh these risks carefully when determining how long you should remain on the medication.

Omeprazole and esomeprazole should not be used alongside clopidogrel, as they can reduce its antiplatelet effect; if you take clopidogrel, inform your prescriber before starting a PPI (see the electronic Medicines Compendium SmPC for omeprazole for full interaction information).

If you experience a suspected side effect from omeprazole, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Typical Duration of Omeprazole Use Following Bariatric Surgery

Most NHS bariatric units prescribe omeprazole for 4–12 weeks post-surgery, with a review at 6–12 weeks; continued use beyond this point requires clinical justification such as persistent GORD.

The duration for which omeprazole is prescribed after a gastric sleeve procedure varies between surgical centres and individual patient circumstances. In UK NHS bariatric practice, many units prescribe omeprazole for approximately 4–12 weeks postoperatively, with a clinical review at 6–12 weeks to determine whether continued treatment is needed. Some centres extend this to six months or beyond, but only where clinically indicated — for example, in patients with ongoing reflux symptoms or confirmed gastro-oesophageal reflux disease (GORD). There is no single universal UK standard, and you should follow the protocol of your own bariatric team.

A broadly representative approach used across NHS bariatric units includes:

• Early postoperative period (weeks 1–6): Omeprazole typically 20 mg once daily to protect the healing gastric lining. A dose of 40 mg once daily may be used for more severe symptoms or confirmed oesophagitis, as per clinical judgement

• Review at 6–12 weeks: Your team will assess symptom control and decide whether to continue, reduce, or stop the medication

• Beyond 12 weeks: Continued use only if clinically indicated — for example, persistent GORD, endoscopic evidence of oesophagitis, or ongoing symptoms

In line with NICE Key Therapeutic Topic KTT13 on proton pump inhibitors, the guiding principle is to use the lowest effective dose for the shortest clinically appropriate duration, with regular review and a step-down or tapering plan where possible.

In the early weeks after surgery, some centres advise using dispersible or orally disintegrating PPI formulations, or opening capsules and mixing the granules with water, to aid swallowing and absorption. Follow your local team's advice on formulation.

Do not stop taking omeprazole abruptly without consulting your GP or bariatric team. Sudden discontinuation can cause rebound acid hypersecretion, temporarily worsening symptoms. A gradual reduction in dose — for example, stepping down to alternate-day dosing before stopping — guided by your clinical team, is the recommended approach.

How Your Surgical Team Reviews and Adjusts Your Prescription

Your bariatric team reviews omeprazole at structured follow-up appointments, assessing symptom burden, nutritional status, magnesium levels, and medication tolerance to decide whether to continue, reduce, or stop the prescription.

After a gastric sleeve, your care is typically managed through a structured follow-up programme coordinated by your bariatric surgical team, which may include a bariatric surgeon, specialist nurse, dietitian, and GP, in line with NHS England's Service Specification for Specialised Severe and Complex Obesity Services. Follow-up timing varies by centre but commonly occurs at around six weeks, three months, six months, and twelve months post-surgery. These reviews are essential not only for monitoring weight loss progress but also for reassessing medications such as omeprazole.

At each follow-up appointment, your team will assess:

• Symptom burden: Whether you are experiencing heartburn, regurgitation, chest discomfort, or difficulty swallowing

• Nutritional status: Blood tests to check for deficiencies in iron, vitamin B12, folate, calcium, and vitamin D — which can be compounded by long-term PPI use — in line with BOMSS nutritional monitoring guidance

• Medication tolerance: Any side effects attributable to omeprazole, such as headaches, diarrhoea, or abdominal discomfort

• Magnesium levels: The MHRA advises considering magnesium monitoring before and periodically during prolonged PPI therapy, particularly if you are also taking digoxin, diuretics, or other medications that affect magnesium levels, or if you develop symptoms such as muscle cramps, fatigue, or palpitations

• Need for further investigation: If symptoms are poorly controlled, your team may recommend an upper gastrointestinal endoscopy to assess the oesophagus and gastric sleeve directly

Your GP plays a central role in ongoing prescription management, particularly once you have been discharged from the specialist bariatric service. It is important to keep your GP informed of any changes in your symptoms and to attend routine medication reviews.

Seek urgent medical attention — contact 999 or go to your nearest emergency department — if you develop any of the following:

• Vomiting blood or passing black, tarry stools (possible gastrointestinal bleeding)

• Severe chest pain

• Sudden, severe abdominal pain

Contact your GP promptly or seek an urgent appointment if you experience:

• Persistent or worsening difficulty swallowing (dysphagia)

• Unexplained or progressive unintentional weight loss

• Persistent vomiting

• New or worsening anaemia

These symptoms may warrant urgent investigation, including referral via the NHS two-week-wait suspected cancer pathway as set out in NICE Guideline NG12 (Suspected cancer: recognition and referral).

Acid Reflux and GORD Risk After Gastric Sleeve

Sleeve gastrectomy can worsen or newly cause GORD due to reduced lower oesophageal sphincter pressure and increased intragastric pressure, potentially requiring long-term PPI therapy or, in severe cases, revisional surgery.

One of the most clinically significant concerns following sleeve gastrectomy is the increased risk of gastro-oesophageal reflux disease (GORD). Unlike Roux-en-Y gastric bypass — which is associated with a reduction in reflux symptoms — sleeve gastrectomy has been shown in multiple studies to worsen or newly induce GORD in a proportion of patients. This is an important consideration when determining the appropriate duration of omeprazole therapy.

The mechanisms underlying post-sleeve GORD are multifactorial and include:

• Reduced lower oesophageal sphincter (LOS) pressure due to removal of the gastric fundus, which normally acts as a pressure buffer

• Increased intragastric pressure within the narrow sleeve, promoting reflux of acidic contents into the oesophagus

• Altered gastric emptying and motility changes that can delay clearance of acid from the oesophagus

• Hiatus hernia, which may be unmasked or worsened by the surgical procedure

• Sleeve stenosis, which can contribute to reflux and should be considered if symptoms are refractory

For patients who develop de novo GORD or experience a significant worsening of pre-existing reflux after sleeve gastrectomy, long-term PPI therapy may be necessary. In some cases, persistent and severe GORD that is unresponsive to medical management may prompt a clinical discussion about revisional bariatric surgery — most commonly conversion to a Roux-en-Y gastric bypass, which tends to resolve reflux symptoms more effectively. This should be discussed with your bariatric team.

Some patients experience laryngopharyngeal symptoms — such as a chronic cough, hoarseness, or a sensation of a lump in the throat — which may be associated with reflux, though the relationship is not always straightforward and requires clinical assessment. If you notice these symptoms after your sleeve gastrectomy, discuss them with your GP or bariatric team. Further information on GORD management in adults is available via NICE Clinical Knowledge Summaries (CKS).

UK Guidance on Long-Term PPI Use After Bariatric Surgery

NICE KTT13 and MHRA guidance recommend using the lowest effective PPI dose for the shortest appropriate duration, with regular review; BOMSS provides UK-specific advice on PPI use after bariatric surgery.

In the UK, the use of proton pump inhibitors following bariatric surgery is informed by a combination of NHS commissioning standards, NICE guidance, MHRA safety advice, and recommendations from specialist bariatric societies, including the British Obesity and Metabolic Surgery Society (BOMSS).

NICE Guideline CG189 (Obesity: identification, assessment and management) emphasises the importance of structured postoperative follow-up and ongoing medical management after bariatric surgery, including regular review of medications in the context of the patient's evolving clinical needs.

NICE Key Therapeutic Topic KTT13 (Proton pump inhibitors) provides clear prescribing principles applicable to post-bariatric patients: use the lowest effective dose, review the need for continued treatment regularly (typically within 4–8 weeks of initiation or change), and implement a step-down or tapering plan when clinically appropriate. NICE Clinical Knowledge Summaries (CKS) on Dyspepsia and GORD provide further practical guidance on PPI indications, dosing, and deprescribing in primary care.

MHRA Drug Safety Updates on PPIs highlight risks associated with long-term use, including hypomagnesaemia, Clostridioides difficile infection, fracture risk, subacute cutaneous lupus erythematosus (SCLE), and interstitial nephritis. Bariatric patients are at heightened risk of nutritional complications, and magnesium monitoring should be considered before and periodically during prolonged PPI therapy, or where risk factors are present (such as concurrent use of digoxin or diuretics). Full prescribing information, including contraindications and interactions, is available in the electronic Medicines Compendium (emc) SmPC for omeprazole.

BOMSS guidance for GPs on medications after bariatric surgery provides UK-specific advice on PPI use, duration, and nutritional monitoring following sleeve gastrectomy and other bariatric procedures, and is a useful resource for both patients and primary care clinicians.

From a practical standpoint, NHS prescribing guidance supports the use of the lowest effective dose of omeprazole for the shortest clinically appropriate duration, with regular review. Patients should not self-discontinue their prescription but should engage with their GP or bariatric team to agree a safe tapering plan when the time is appropriate.

If you are unsure whether you still need omeprazole, or if your symptoms have changed, book a medication review with your GP — this is a routine and important part of your long-term post-surgical care. If you experience a suspected side effect from omeprazole, please report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions